Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?
Overview
Authors
Affiliations
Introduction: Pulmonary hypertension (PH) is a well-recognised complication of interstitial lung diseases (ILD), which worsens prognosis and impairs exercise capacity. Echocardiography is the most widely used, non-invasive method for PH assessment. The aim of our study was to identify the factors predictive for echocardiographic signs of PH in newly recognised ILD patients.
Methods: Ninety-three consecutive patients (28F/65M) with different ILD were prospectively evaluated from January 2009 to March 2014. Pulmonary function testing, 6-min walk distance (6MWD), initial and sixth minute room air oxygen saturation, NT-proBNP and echocardiography were assessed in each patient. Echocardiographic PH probability was determined according to the 2009 ESC/ERS guidelines.
Results: In 41 patients (Group B) increased PH possibility has been diagnosed on echocardiography, in 52 patients (Group A)-low PH probability. Most pronounced differences (p ≤ 0.0005) between groups B and A concerned: age, 6MWD, room air oxygen saturation at 6 min, DLCO and TLC/DLCO index (57.6 vs 43.8 years; 478 vs 583 m; 89.1% vs 93.4%; 54.8% predicted vs 70.5% predicted and 1.86 vs 1.44; respectively). Univariate analysis showed four-fold increased probability of PH when TLC/DLCO exceeded 1.67. A scoring system incorporating age, TLC/DLCO index, 6MWD and room air oxygen saturation at 6 min provided high diagnostic utility, AUC 0.867 (95% CI 0.792-0.867).
Conclusion: ILD patients with TLC/DLCO index > 1.67 have a high likelihood of PH and should undergo further evaluation. The composite model of PH prediction, including age, 6-min walk test and TLC/DLCO was highly specific for recognition of PH on echocardiography.
Kim H, Chandel A, King C, Kim M, Shawabkeh M, Arunachalam A Lung. 2025; 203(1):27.
PMID: 39841267 PMC: 11754375. DOI: 10.1007/s00408-024-00783-2.
Vitulo P, Piccari L, Wort S, Shlobin O, Kovacs G, Vizza C Pulm Circ. 2024; 14(4):e70005.
PMID: 39659477 PMC: 11629413. DOI: 10.1002/pul2.70005.
Arvanitaki A, Diller G, Gatzoulis M, McCabe C, Price L, Wort S Eur Respir Rev. 2024; 33(174).
PMID: 39384306 PMC: 11462299. DOI: 10.1183/16000617.0092-2024.
Pulmonary hypertension associated with lung diseases.
Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E Eur Respir J. 2024; 64(4).
PMID: 39209469 PMC: 11525344. DOI: 10.1183/13993003.01200-2024.
Arslan A, Smith J, Qureshi M, Uysal A, Patel K, Herazo-Maya J Front Med (Lausanne). 2024; 10:1306032.
PMID: 38298504 PMC: 10827954. DOI: 10.3389/fmed.2023.1306032.